Sat, 5 Sep 2026
Markets
DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14% DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14%
Pentagon rescinds new testosterone screening policy without explanation

Pentagon rescinds new testosterone screening policy without explanation

The Pentagon says the guidance is being updated after being online for one day.

Following Defense Secretary Pete Hegseth's startling announcement in July that the US military would begin mandatory testosterone screening for personnel, the Pentagon released a clinical guidance document on September 2 outlining the new medically questionable policy.

The next day, though, the clinical guidance document disappeared, as did an accompanying statement by spokesperson Sean Parnell. The withdrawal was first reported by Reuters.

In a statement sent to Ars Technica, the Pentagon said that the document, titled "Clinical Guidance for Health and Human Performance Optimization," had been temporarily rescinded on September 3 to allow for updates.

Read full article

Comments